Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Administration of the K<sub>Ca</sub> channel activator SKA-31 improves long-term endothelial function, blood pressure regulation and cardiac performance in rats with type 2 diabetes.

Metabolism: clinical and experimental·2025
Same author

Comparison between response surface methodology and Taguchi method for dyeing process parameters optimization in fabric manufacturing by empirical planning.

Scientific reports·2025
Same author

The influence of functional polymorphic positions of HLA-DRβ1 molecules on risk for South Indian systemic lupus erythematosus patients.

Lupus·2018
Same author

Association of IL -6 -174 G>C polymorphism with the risk of SLE among south Indians: evidence from case-control study and meta-analysis.

Lupus·2017
Same author

Association of Aberrations in One Carbon Metabolism with Intimal Medial Thickening in Patients with Type 2 Diabetes Mellitus.

Indian journal of clinical biochemistry : IJCB·2015
Same author

Association of TLR4 (D299G, T399I), TLR9 -1486T>C, TIRAP S180L and TNF-α promoter (-1031, -863, -857) polymorphisms with risk for systemic lupus erythematosus among South Indians.

Lupus·2014
Same journal

Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants.

The pharmacogenomics journal·2026
Same journal

Beyond the 'Pregnancy Black Box': a global roadmap for artificial intelligence-driven pharmacogenomics in maternal-neonatal health.

The pharmacogenomics journal·2026
Same journal

The association of ABCB1, CYP2C19 and CYP2C9 combined activity with clopidogrel resistance in patients with recurrent ischemic stroke.

The pharmacogenomics journal·2026
Same journal

Development and validation of an open data model for pharmacogenetics to enable semantic interoperability in clinical practice.

The pharmacogenomics journal·2026
Same journal

Finasteride, pharmacogenomics, and suicide risk: a public health concern.

The pharmacogenomics journal·2026
Same journal

Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia.

The pharmacogenomics journal·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Optimization of warfarin dose by population-specific pharmacogenomic algorithm.

A Pavani1, S M Naushad, Y Rupasree

  • 1Department of Clinical Pharmacology and Therapeutics, Nizam's Institute of Medical Sciences, Hyderabad, India.

The Pharmacogenomics Journal
|March 2, 2011
PubMed
Summary
This summary is machine-generated.

A new population-specific algorithm optimizes warfarin dosing by using genetic information and vitamin K intake. This pharmacogenomic approach improves accuracy and reduces adverse effects from incorrect warfarin doses.

Related Experiment Videos

Last Updated: Jun 4, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology

Background:

  • Warfarin dosing requires careful management to achieve therapeutic international normalized ratio (INR) and minimize bleeding risks.
  • Existing warfarin dosing algorithms have limitations in accuracy across diverse populations.

Purpose of the Study:

  • To develop and validate a population-specific pharmacogenomic algorithm for optimizing warfarin dosage.
  • To improve the accuracy and clinical utility of warfarin dosing compared to existing methods.

Main Methods:

  • A multiple linear regression model was employed using vitamin K intake and genetic polymorphisms in CYP2C9 (*2, *3) and VKORC1 (*3, *4, D36Y, -1639 G>A) as predictors.
  • The newly developed algorithm was validated against established algorithms (Wadelius, IWC, Gage) and therapeutic warfarin dose.

Main Results:

  • The new algorithm demonstrated superior accuracy (0.89 overall) compared to clinical data (0.51).
  • It showed significantly improved sensitivity (0.87) and specificity (0.93) in predicting therapeutic warfarin response.
  • The algorithm substantially reduced both overestimation (0.06) and underestimation (0.13) of the required warfarin dose.

Conclusions:

  • The developed population-specific pharmacogenomic algorithm offers enhanced clinical utility for optimizing warfarin dosing.
  • This approach can lead to decreased adverse events associated with suboptimal warfarin therapy.